Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)

NCT06855628 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT06855628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment Of A Novel Metabolic Imaging Modalities As A Predictor Of Therapeutic Efficacy In Glioblastoma (GBM)
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2025
Completion date
July 13, 2026
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioma